{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116420","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.294182+00:00","generated_at":"2026-05-30T02:34:40.413385+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics Q3 2024: completes VIRAGE enrollment, cash $16.4M, impairment charges","bullets":["Completed enrollment of 92 evaluable patients in VIRAGE Phase 2b trial of VCN-01 in metastatic pancreatic ductal adenocarcinoma.","Cash and cash equivalents totaled $16.4M at Sep 30, 2024, down from $23.2M at Dec 31, 2023.","R&D expenses decreased 32% to $2.7M; G&A expenses increased to $2.3M partly due to contingent consideration adjustments.","Recorded impairment charges of $1.3M on in-process R&D and $1.5M on goodwill due to decline in stock price.","Discussions initiated with regulators to potentially expand VIRAGE into Phase 3 registrational trial; also positive progress in retinoblastoma program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116420","json":"https://secwatch.observer/filing/0001104659-24-116420.json","markdown":"https://secwatch.observer/filing/0001104659-24-116420.md","text":"https://secwatch.observer/filing/0001104659-24-116420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/0001104659-24-116420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465924116420/tm2426982d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:34:40.413385+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}